Literature DB >> 2017613

Rhodococcus equi infection in patients with and without human immunodeficiency virus infection.

R L Harvey1, J C Sunstrum.   

Abstract

Rhodococcus equi is an uncommon pathogen in humans that has occasionally been reported to cause infection in individuals with impaired cellular immunity. We summarize 30 previously published reports of human infection with R. equi and describe one additional case in a patient with AIDS. Eleven (35%) of the patients discussed in this report had AIDS or human immunodeficiency virus (HIV) infection, which is emerging as the leading cause of immunosuppression in cases of R. equi infection. Seventy-seven percent of all patients had pneumonia due to R. equi, and the infiltrate frequently cavitated. When HIV-infected patients were compared with those not infected with the virus, symptoms, age, and frequency of pneumonia were similar. Sputum and blood cultures were more likely to be positive in HIV-infected patients. Individuals with HIV infection also had a higher incidence of simultaneous secondary infections and higher mortality than non-HIV-infected patients (54.5% vs. 20%). The rate of survival for all patients was 75% when antibiotics were combined with surgical resection of infected tissue; in comparison, the survival rate among patients receiving antibiotics alone was 61.1%.

Entities:  

Mesh:

Year:  1991        PMID: 2017613     DOI: 10.1093/clinids/13.1.139

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  43 in total

1.  In vitro activities of polycationic peptides alone and in combination with clinically used antimicrobial agents against Rhodococcus equi.

Authors:  A Giacometti; O Cirioni; F Ancarani; M S Del Prete; M Fortuna; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  DNA sequence and comparison of virulence plasmids from Rhodococcus equi ATCC 33701 and 103.

Authors:  S Takai; S A Hines; T Sekizaki; V M Nicholson; D A Alperin; M Osaki; D Takamatsu; M Nakamura; K Suzuki; N Ogino; T Kakuda; H Dan; J F Prescott
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

3.  Pulmonary abscess due to a rifampin and fluoroquinolone resistant Rhodococcus equi strain in a HIV infected patient.

Authors:  P Nordmann; E Rouveix; M Guenounou; M H Nicolas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-06       Impact factor: 3.267

4.  Caring for pets of immunocompromised persons.

Authors:  F J Angulo; C A Glaser; D D Juranek; M R Lappin; R L Regnery
Journal:  Can Vet J       Date:  1995-04       Impact factor: 1.008

5.  Monooxygenase-like sequence of a Rhodococcus equi gene conferring increased resistance to rifampin by inactivating this antibiotic.

Authors:  S J Andersen; S Quan; B Gowan; E R Dabbs
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

6.  Rhodococcus equi infection during treatment of a c-ANCA positive vasculitis: a case report.

Authors:  Elizabeth A Garthwaite; David J Border; Colin H Jones; David P Worth
Journal:  Rheumatol Int       Date:  2006-09-30       Impact factor: 2.631

7.  Immunoglobulin G subisotype responses of pneumonic and healthy, exposed foals and adult horses to Rhodococcus equi virulence-associated proteins.

Authors:  Kathleen E Hooper-McGrevy; Bruce N Wilkie; John F Prescott
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

8.  Identification of intermediately virulent Rhodococcus equi isolates from pigs.

Authors:  S Takai; N Fukunaga; S Ochiai; Y Imai; Y Sasaki; S Tsubaki; T Sekizaki
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

9.  Failure of pulmonary clearance of Rhodococcus equi infection in CD4+ T-lymphocyte-deficient transgenic mice.

Authors:  S T Kanaly; S A Hines; G H Palmer
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

10.  Role of T-lymphocyte subsets in Rhodococcus equi infection.

Authors:  P Nordmann; E Ronco; C Nauciel
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.